Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study
Titel:
Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study
Auteur:
Gazzah, A. Bedard, P.L. Hierro, C. Kang, Y.-K. Abdul Razak, A. Ryu, M.-H. Demers, B. Fagniez, N. Henry, C. Hospitel, M. Soria, J.-C. Tabernero, J.